US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Articles published by Zealand Pharma

< Previous 1 2 3 4 5 6 Next >
News headline image
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
From Zealand Pharma
Via GlobeNewswire
News headline image
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces closing of collaboration and license agreement with Roche
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma Announces Financial Results for the First Three Months of 2025
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery
From Zealand Pharma
Via GlobeNewswire
News headline image
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025
From Zealand Pharma
Via GlobeNewswire
News headline image
Total number of shares and voting rights in Zealand Pharma as of March 31, 2025
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma Announces Financial Results for the Full Year 2024
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results
From Zealand Pharma
Via GlobeNewswire
News headline image
Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th
From Zealand Pharma
Via GlobeNewswire
News headline image
U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma to participate in the Jefferies London Healthcare Conference
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma Announces Financial Results for the First Nine Months of 2024
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide
From Zealand Pharma
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >